IP Library Granted Patent US 10,709,592
Granted Patent B2
US 10,709,592 · App. 15/796,581 · Granted Jul 14, 2020

Ultrasonic systems and methods for locating and/or characterizing intragastric devices

Inventors: Mark C. Brister (Encinitas, CA); Neil R. Drake (San Diego, CA); Sheldon Nelson (Vista, CA)
Assignee: Obalon Therapeutics, Inc.
A61F5/0046A61F5/003A61F5/0036A61F5/0043A61F2005/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,592
App. No.
15/796,581
Granted
Jul 14, 2020
Kind
B2
Abstract

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided.

Claims (29)

1. An intragastric balloon configured to have a useful life in an in vivo gastric environment of at least 30 days, comprising:

a component configured for detection by an ultrasonic detector;

a swallowable inflatable intragastric balloon comprising a polymeric wall configured to have, under conditions of an in vivo gastric environment, a permeability to CO 2 of more than 10 cc/m 2 /day, and a lumen;

a swallowable outer container comprising the balloon in a deflated and folded compacted state; and

a self-sealing valve attached to an inner surface of the polymeric wall and configured for introducing the initial fill fluid into the lumen of the intragastric balloon in the in vivo gastric environment;

wherein the component configured for detection by an ultrasonic detector comprises a first coiled conductor coupled with the intragastric balloon and a second coiled conductor separate from the intragastric balloon, and wherein the ultrasonic detector comprises a spectrum analyzer configured to measure resonant frequencies associated with the intragastric balloon.

2. The intragastric balloon of claim 1 , wherein the polymeric wall is configured to have, under conditions of an in vivo gastric environment, a permeability to CO 2 of more than 50 cc/m 2 /day.

3. The intragastric balloon of claim 1 , further comprising a catheter.

4. The intragastric balloon of claim 3 , wherein the catheter is a component of an outer container-catheter assembly.

5. The intragastric balloon of claim 3 , wherein the catheter is coupled to the self-sealing valve.

6. The intragastric balloon of claim 1 , further comprising an inflation fluid container comprising an inflation fluid.

7. The intragastric balloon of claim 6 , wherein the inflation fluid comprises at least one of N 2 , SF 6 , C 2 F 6 , C 3 F 8 , C 4 F 10 , C 4 F 8 , C 3 F 6 , CF 4 , and CClF 2 —CF 3 .

8. The intragastric balloon of claim 6 , wherein the inflation fluid comprises an inert gas.

9. The intragastric balloon of claim 6 , wherein the inflation fluid is a liquid.

10. The intragastric balloon of claim 1 , further comprising a component configured to deflate the intragastric balloon at the end of a pre-determined useful life in vivo.

11. The intragastric balloon of claim 10 , wherein the pre-determined useful life is at least 30 days.

12. A method for positioning an intragastric balloon, comprising:

introducing into a patient, via swallowing, a swallowable intragastric balloon comprising a component configured for detection by an ultrasonic detector, a polymeric wall configured to have, under conditions of an in vivo gastric environment, a permeability to CO 2 of more than 10 cc/m 2 /day, a lumen, and a self-sealing valve attached to an inner surface of the polymeric wall and configured for introducing the initial fill fluid into the lumen in the in vivo gastric environment;

confirming, by sensing resonant frequencies associated with the intragastric balloon in a compacted, solid form, a location of the intragastric balloon, wherein the location is the patient's stomach; thereafter

introducing an inflation fluid into a lumen of the intragastric balloon;

after introducing the inflation fluid, confirming, by sensing resonant frequencies associated with the intragastric balloon in inflated form, complete inflation of the intragastric balloon;

exposing the intragastric balloon in inflated form to the in vivo intragastric environment for a useful life of at least 30 days, wherein the intragastric balloon maintains a volume of 75% to 125% of its original nominal volume over the useful life; and

after the exposing the intragastric balloon in inflated form to the in vivo intragastric environment, deflating the intragastric balloon, wherein the deflating comprises bursting the intragastric balloon by administration of an ultrasonic or acoustic pulse.

13. The method of claim 12 , wherein the inflation fluid comprises at least one of N 2 , SF 6 , C 2 F 6 , C 3 F 8 , C 4 F 10 , C 4 F 8 , C 3 F 6 , CF 4 , and CClF 2 —CF 3 .

14. The method of claim 12 , wherein the inflation fluid comprises a liquid.

15. The method of claim 12 , wherein the ultrasonic component comprises a first coiled conductor coupled with the intragastric balloon and a second coiled conductor separate from the intragastric balloon, and wherein the ultrasonic detector comprises a spectrum analyzer configured to measure resonant frequencies associated with the intragastric balloon.

16. The method of claim 12 , wherein the polymeric wall is configured to have, under conditions of an in vivo gastric environment, a permeability to CO 2 of more than 50 cc/m 2 /day.

17. The method of claim 12 , wherein the useful life is at least 90 days.

18. The method of claim 12 , further comprising, during the exposing the intragastric balloon to the in vivo intragastric environment, a degree of inflation of the intragastric balloon.

Assignments (3)
SECURITY INTEREST Recorded Oct 24, 2024
From: RESHAPE LIFESCIENCES INC.
To: ASCENT PARTNERS FUND LLC
Reel/Frame 070166/0882 →
CHANGE OF NAME Recorded Oct 6, 2021
From: OBALON THERAPEUTICS, INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 057726/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: BRISTER, MARK C.; DRAKE, NEIL R.; NELSON, SHELDON; PROCTOR, DANIEL J.
To: OBALON THERAPEUTICS, INC.
Reel/Frame 044564/0376 →
Continuity (3)
Continuation 14877846 · Oct 7, 2015
Provisional Application 62062081 · Oct 9, 2014
Related Publication 20180049901A1 · Feb 22, 2018
Cited By (2)
US 12,440,358 US 12,514,464